A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

Type of Cancer
Multiple Myeloma

Site
Bethesda

Sponsor
Celgene

Protocol Number
MEDI4736-MM-003

To Learn More Call
201-510-0910